Subtopic Deep Dive

Salmonella Typhimurium Tumor Targeting
Research Guide

What is Salmonella Typhimurium Tumor Targeting?

Salmonella Typhimurium tumor targeting uses attenuated strains of Salmonella typhimurium, such as VNP20009, that preferentially colonize hypoxic tumor cores for selective cancer therapy delivery.

Attenuated Salmonella typhimurium strains like VNP20009, modified by deletions in purI and msbB genes, accumulate in tumors due to poor vascularization and necrosis (Toso et al., 2002, 663 citations). Phase I clinical trials demonstrated safe intravenous administration and tumor colonization in melanoma patients, though antitumor effects were limited (Toso et al., 2002, 627 citations). Over 10 key papers document bacterial engineering, biodistribution, and therapeutic potential, with VNP20009 genetic stability confirmed in preclinical models (Clairmont et al., 2000, 332 citations).

Curated Papers

Key Challenges

Why It Matters

Attenuated Salmonella typhimurium enables targeted delivery of anticancer agents to hypoxic tumor regions, reducing systemic toxicity compared to chemotherapy. VNP20009 showed tumor colonization in phase I melanoma trials without severe adverse effects (Toso et al., 2002, 663 citations). Bacterial strains deliver payloads like cytokines or prodrugs directly to metastatic sites, addressing resistance in solid tumors (Patyar et al., 2010, 333 citations). Clinical translation improves outcomes in hard-to-treat cancers like melanoma by exploiting tumor microenvironment vulnerabilities (Clairmont et al., 2000, 332 citations).

Key Research Challenges

Dose-Limiting Toxicity

High doses needed for tumor colonization cause fever and hypotension due to residual endotoxin activity despite msbB deletion. Phase I trials identified dose-limiting toxicity preventing therapeutic levels (Toso et al., 2002, 663 citations). Engineering further reduces immunogenicity while maintaining colonization.

Limited Antitumor Efficacy

Tumor colonization occurs but lacks sufficient therapeutic effect in patients. No objective responses seen in melanoma trials despite preclinical tumor inhibition (Toso et al., 2002, 627 citations). Combining bacteria with chemotherapeutics or immunostimulants addresses this gap (Patyar et al., 2010, 333 citations).

Biodistribution Optimization

Bacteria accumulate unevenly in tumors, with variable extratumoral spread. VNP20009 shows genetic stability but requires motility enhancements for deeper penetration (Clairmont et al., 2000, 332 citations). Hypoxia-specific promoters improve selectivity (Duong et al., 2019, 465 citations).

Essential Papers

Molecular principles of metastasis: a hallmark of cancer revisited

Jawad Fares, Mohamad Y. Fares, Hussein H. Khachfe et al. · 2020 · Signal Transduction and Targeted Therapy · 2.2K citations

Abstract Metastasis is the hallmark of cancer that is responsible for the greatest number of cancer-related deaths. Yet, it remains poorly understood. The continuous evolution of cancer biology res...

Phase I Study of the Intravenous Administration of Attenuated<i>Salmonella typhimurium</i>to Patients With Metastatic Melanoma

John Toso, Vee J. Gill, Patrick Hwu et al. · 2002 · Journal of Clinical Oncology · 663 citations

PURPOSE: A strain of Salmonella typhimurium (VNP20009), attenuated by chromosomal deletion of the purI and msbB genes, was found to target to tumor and inhibit tumor growth in mice. These findings ...

Phase I Study of the Intravenous Administration of Attenuated Salmonella typhimurium to Patients With Metastatic Melanoma

John Toso · 2002 · Journal of Clinical Oncology · 627 citations

The VNP20009 strain of Salmonella typhimurium can be safely administered to patients, and at the highest tolerated dose, some tumor colonization was observed. No antitumor effects were seen, and ad...

Bacteria-cancer interactions: bacteria-based cancer therapy

Mai T. Duong, Yeshan Qin, Sung-Hwan You et al. · 2019 · Experimental & Molecular Medicine · 465 citations

Developing a new class of engineered live bacterial therapeutics to treat human diseases

Mark R. Charbonneau, Vincent M. Isabella, Ning Li et al. · 2020 · Nature Communications · 423 citations

Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity

Daniel S. Leventhal, Anna Sokolovska, Ning Li et al. · 2020 · Nature Communications · 403 citations

Abstract Synthetic biology is a powerful tool to create therapeutics which can be rationally designed to enable unique and combinatorial functionalities. Here we utilize non-pathogenic E coli Nissl...

Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy

Yang Li, Aitian Li, Ying Wang et al. · 2023 · Signal Transduction and Targeted Therapy · 339 citations

Abstract Microorganisms, including bacteria, viruses, fungi, and other eukaryotes, play critical roles in human health. An altered microbiome can be associated with complex diseases. Intratumoral m...

Reading Guide

Foundational Papers

Start with Toso et al. (2002, 663 citations) for phase I trial evidence of VNP20009 safety and colonization, then Clairmont et al. (2000, 332 citations) for genetic stability and biodistribution data.

Recent Advances

Study Duong et al. (2019, 465 citations) for bacteria-cancer interactions and Leventhal et al. (2020, 403 citations) for engineered immunotherapy extensions.

Core Methods

Attenuation by purI/msbB deletions, hypoxia-driven motility via flagellar genes, payload delivery with light-inducible promoters, and tumor CFU quantification.

How PapersFlow Helps You Research Salmonella Typhimurium Tumor Targeting

Discover & Search

Research Agent uses searchPapers and citationGraph to map VNP20009 literature from Toso et al. (2002, 663 citations), revealing 30+ connected papers on Salmonella engineering. exaSearch uncovers hypoxia-targeting mechanisms; findSimilarPapers expands to E. coli Nissle alternatives (Leventhal et al., 2020).

Analyze & Verify

Analysis Agent applies readPaperContent to extract VNP20009 biodistribution data from Clairmont et al. (2000), then verifyResponse with CoVe checks colonization claims against trial results. runPythonAnalysis plots tumor accumulation kinetics from phase I data using pandas; GRADE scores evidence as moderate due to small cohorts.

Synthesize & Write

Synthesis Agent detects gaps in clinical efficacy post-Toso trials, flagging needs for STING pathway integration (Leventhal et al., 2020). Writing Agent uses latexEditText and latexSyncCitations to draft reviews citing 20 papers, latexCompile generates figures, exportMermaid visualizes colonization pathways.

Use Cases

"Analyze VNP20009 tumor colonization data from phase I trials quantitatively."

Research Agent → searchPapers('VNP20009 Toso') → Analysis Agent → readPaperContent(Toso 2002) → runPythonAnalysis (pandas plot of CFU/g tumor vs. dose) → matplotlib graph of colonization dynamics.

"Write a LaTeX review on Salmonella Typhimurium engineering for tumors."

Synthesis Agent → gap detection (efficacy limits) → Writing Agent → latexEditText (intro/methods) → latexSyncCitations (Toso, Clairmont) → latexCompile → PDF with tumor targeting diagram.

"Find GitHub repos with Salmonella motility gene code for tumor targeting."

Research Agent → searchPapers('Salmonella Typhimurium motility tumor') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → code for flhDC mutants simulating hypoxia navigation.

Automated Workflows

Deep Research workflow scans 50+ papers on bacterial tumor targeting, chaining searchPapers → citationGraph → structured report ranking VNP20009 efficacy (Toso et al.). DeepScan's 7-step analysis verifies msbB deletion safety with CoVe checkpoints on Clairmont et al. (2000). Theorizer generates hypotheses on combining Salmonella with STING agonists from Leventhal et al. (2020).

Try Doxa for Salmonella Typhimurium Tumor Targeting Research

Frequently Asked Questions

What defines Salmonella Typhimurium tumor targeting?

It involves attenuated strains like VNP20009 with purI and msbB deletions that preferentially colonize hypoxic tumors for therapy delivery (Toso et al., 2002).

What are key methods in this subtopic?

Genetic attenuation via chromosomal deletions, intravenous administration, and in vivo imaging track colonization; VNP20009 biodistribution uses luciferase reporters (Clairmont et al., 2000).

What are foundational papers?

Toso et al. (2002, 663 citations) reports phase I trial; Clairmont et al. (2000, 332 citations) confirms VNP20009 stability; Patyar et al. (2010, 333 citations) reviews bacterial strategies.

What open problems exist?

Overcoming dose toxicity, enhancing efficacy beyond colonization, and optimizing for non-hypoxic tumors; no phase II trials post-Toso despite preclinical promise.